Description

UCSF CME: 10th Annual California Heart Rhythm Symposium

YOU WILL GET THE COURSE VIA LIFETIME DOWNLOAD LINK (FAST SPEED) AFTER PAYMENT

Course duration: Over 11 Hours of videos

September 13-14  2019

Topics And Speakers:

UCSF CME: 10th Annual California Heart Rhythm Symposium
List of Titles
+—Atrial Filibration
| 01 Mechanism of AF Using Integrated Optical and Multi-Electrode Mapping of Human Hearts.ts
| 02 Atrial Fibrillation – What Are the Risk Factors and How to Prevent AF.ts
| 03 Catheter Ablation of AF – Will it Prevent Dementia.ts
| 04 Should We Be Anticoagulating the CHA2DS2-VASc 1 Patient.ts
| 05 Catheter Ablation of AF – Expected Outcomes with Cryoballoon vs. RF.ts
| 06 Ablation of Persistent AF – What to Do Beyond PV Isolation.ts
| 07 Role of Endocardial vs. Epicardial LAA Isolation.ts
| 08 Should We Be Ablating Asymptomatic AF.ts
| 09 Atrial Filibration Panel Discussion.ts
| 10 Electrical Isolation of the LAA Should Be Performed Empirically in Long-standing Persistent AF Patients.ts
| 11 Electrical Isolation of the LAA Should NOT Be Performed Empirically in Long-standing Persistent AF Patients.ts
|
+—Cardiac Sarcoidosis ARVD
| 01 Pulmonary Evaluation of Sarcoidosis.ts
| 02 Rheumatologic Evaluation and Treatment of Cardiac Sarcoidosis.ts
| 03 Evaluation and Management of Heart Rhythm Disorders in Patients with Cardiac Sarcoidosis.ts
| 04 Arrhythmogenic Right Ventricular Cardiomyopathy – Diagnosis.ts
| 05 ARVD Therapy.ts
| 06 Arrhythmogenic RV Cardiomyopathy – Ablation Therapy.ts
| 07 Cardiac Sarcoidosis Panel Discussion – Controversies.ts
|
+-–Inherited Arrhythmias
| 01 Redefining Sudden Cardiac Death – Insights from the San Francisco Postmortem Systematic Investigation of Sudden Cardiac Death Study.ts
| 02 Interventional Therapies to “Cure” Brugada Syndrome.ts
| 03 A LifeVest Should be Placed for Post-Infarction Patients with EF less than 35.ts
| 04 A LifeVest Should NOT be Placed for Post-Infarction Patients with EF less than 35%.ts
| 05 A LifeVest Should be Placed for Post-Infarction Patients with EF less than 35%.ts
|
+—New Therapies for Heart Failure
| 01 When to use S-ICD and Novel Pacing Approaches.ts
| 02 When and How to Perform His Bundle,LBB Pacing.ts
| 03 AF and CHF – Should Ablation Be First Line Therapy.ts
| 04 When to Consider ICD in the DCM Patient without Arrhythmias.ts
| 05 Wearables and Arrhythmias – Where Are We Headed.ts
| 06 New Therapies for Heart Failure Panel Discussion.ts
| 07 HIS-Bundle Pacing Should Be First Line Therapy for AV Block with Preserved LV Function.ts
| 08 HIS-Bundle Pacing Should NOT Be First Line Therapy for AV Block with Preserved LV Function.ts
| 09 HIS-Bundle Pacing Debate.ts
|
\—Ventricular Tachycardia
01 VT Mechanisms.ts
02 Surface ECG Recognition-Localization of Idiopathic VT.ts
03 Tips and Tricks for Mapping and Ablation of LV Summit and Intramural PVCs and VT.ts
04 Ventricular Tachycardia in Patients with an LVAD – Is There a Role for Prophylactic Ablation.ts
05 Neuromodulatory Therapies for Ventricular Tachycardia.ts
06 Stereotactic Body Radiation Therapy for Treatment of Refractory VT.ts
07 Panel Discussion – When to use “Bailout” Approaches.ts
08 Debate – Should VT Ablation Be the First Line Therapy Before ICD Implant in Patients Presenting with Monomorphic Ventricular Tachycardia.ts
09 VT Ablation Should NOT Be First Line Therapy Before ICD Implant in Patients Presenting with Monomorphic Ventricular Tachycardia.ts
10 VT Ablation Should Be First Line Therapy Before ICD Implant in Patients Presenting with Monomorphic Ventricular Tachycardia Rebuttals.ts